Coronado Biosciences sell-off unwarranted, says Oppenheimer

theflyonthewall.com

After Coronado's stock dropped significantly yesterday, Oppenheimer is not aware of any events or development that would justify the weakness. The firm reiterates a $12 price target and Outperform rating on the stock.

Rates

View Comments (0)